Accueil   Diary - News   All news ElsaLys confirms the renew of its cohort ATU in France

ElsaLys confirms the renew of its cohort ATU in France

 

While ElsaLys continues to work on the filing of marketing approval in Europe and the U.S. for inolimomab, the company confirms the renew of its cohort ATU in France and compassionate use programs submissions in several other countries

 

 

  • During its first year under ATU and despite the pandemic, around 30 patients in France has been treated with inolimomab as it is considered a reliable treatment for acute cortico-resistant or corticosteroid-dependent graft-versus-host disease in adults and pediatric patients over 28 days of age.
  • ElsaLys is working on expanding compassionate use programs for inolimomab in several other countries in Europe.

 

Read the press release